The Cooper Companies, Inc. $COO Stock: Sustainable Growth Advisers LP Reduces Stake

Sustainable Growth Advisers LP reduced its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 23.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,492,568 shares of the medical device company’s stock after selling 455,540 shares during the quarter. Cooper Companies comprises approximately 0.9% of Sustainable Growth Advisers LP’s holdings, making the stock its 25th largest position. Sustainable Growth Advisers LP’s holdings in Cooper Companies were worth $84,375,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Cooper Companies in the second quarter worth $1,077,762,000. Generation Investment Management LLP bought a new position in shares of Cooper Companies during the second quarter worth $356,304,000. Jupiter Topco LLC purchased a new position in Cooper Companies during the second quarter valued at $305,074,000. JANA Partners Management LP grew its stake in Cooper Companies by 0.5% during the second quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock valued at $256,900,000 after acquiring an additional 17,322 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Cooper Companies by 3.1% during the second quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock valued at $248,758,000 after acquiring an additional 103,044 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

NASDAQ:COO opened at $57.40 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The stock’s 50 day simple moving average is $63.78 and its two-hundred day simple moving average is $66.20. The company has a market cap of $10.91 billion, a price-to-earnings ratio of 19.59, a PEG ratio of 2.23 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has approved a stock repurchase program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This buyback authorization permits the medical device company to repurchase up to 22.7% of its shares through open market purchases. Share buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Piper Sandler reiterated a “neutral” rating on shares of Cooper Companies in a research note on Thursday. William Blair downgraded shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday, September 10th. Mizuho set a $75.00 price objective on Cooper Companies and gave the company an “outperform” rating in a research report on Thursday, September 10th. Finally, UBS Group cut their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $68.60.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Paul Keel purchased 4,701 shares of Cooper Companies stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $53.18 per share, for a total transaction of $249,999.18. Following the completion of the transaction, the director owned 4,701 shares of the company’s stock, valued at approximately $249,999.18. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence Kurzius bought 10,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of $53.91 per share, for a total transaction of $539,100.00. Following the completion of the transaction, the director directly owned 21,099 shares in the company, valued at approximately $1,137,447.09. This represents a 90.10% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is owned by corporate insiders.

About Cooper Companies

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.